rethinkTHC Search
Menu
Study breakdown

THC appears to cause and worsen psychosis while CBD may have therapeutic potential, but evidence is limited

Systematic ReviewModerate evidence
The takeaway

A systematic review of 12 studies found 10 supporting a causal link between cannabis and schizophrenia, 8 showing symptom worsening, and 6 supporting therapeutic effects of CBD.

Psychiatrists, psychosis researchers, and cannabis policy makers interested in THC-CBD distinctions.

10 of 12 studies supported causal link; 6 supported CBD therapeutic effects

What the researchers found

After screening 96 articles and including 12 final studies (5 traditional reviews, 2 systematic reviews, 2 meta-analyses, 3 observational), 10 studies supported a causative link between cannabis and schizophrenia, 8 supported symptom exacerbation, and 6 supported therapeutic effects of CBD. The evidence points to THC as the primary risk component while CBD may counteract psychotic symptoms.

Why it matters

The opposing effects of THC and CBD on psychosis may explain why cannabis research has yielded contradictory findings. Separating these components could transform both risk assessment and treatment.

The numbers in context

96 initial results; 12 final studies included; 10 supported causative link; 8 supported exacerbation; 6 supported CBD therapeutic effects.

How the study worked

Systematic review of PubMed, PubMed Central, Cochrane Library, and Google Scholar for studies on cannabis and schizophrenia/psychosis published in the last 5 years. Quality assessment reduced 24 studies to 12 final inclusions.

What this study cannot tell us

Half the initial studies excluded for low quality; included studies were mostly reviews themselves (limited original data); small total evidence base (12 studies); did not quantify effect sizes.

How to read the evidence

Moderate: systematic methodology but many included studies were themselves reviews, and half of screened studies were excluded for low quality.

When this study was published

Published 2020.

The bigger picture

The consistent finding that THC increases psychosis risk while CBD may reduce it has direct implications for cannabis product regulation. High-THC/low-CBD products, increasingly common in legal markets, may carry the greatest risk.

Questions still open

  • Would high-CBD/low-THC cannabis products carry less psychosis risk? Could CBD be developed as an adjunct treatment for schizophrenia?

Common questions

Does cannabis cause schizophrenia?
This review found 10 of 12 studies supported a causal link, with THC identified as the primary risk component in genetically vulnerable individuals. However, the authors note the evidence is still not conclusive and more controlled studies are needed.
Can CBD help treat psychosis?
Six of 12 studies in this review supported therapeutic effects of CBD on psychotic symptoms. However, the data was described as minimal and further research on safety and efficacy is needed.

Read the original research

The Association Between Cannabis Use and Schizophrenia: Causative or Curative? A Systematic Review.

Cureus, 12(7), e9309

Citation

Patel, Shweta; Khan, Sahar; M, Saipavankumar; Hamid, Pousettef. (2020). The Association Between Cannabis Use and Schizophrenia: Causative or Curative? A Systematic Review.. Cureus, 12(7), e9309. https://doi.org/10.7759/cureus.9309

Explore the wider topic